Research article · 15 Apr 2026
Conference abstractPublished 20 Aug 2012
Diversity of endocytic trafficking and degradation of angiotensin type I receptor directed by its ligand and heterodimerization partners
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A ctivation of angiotensin type I receptor (AT1R) triggers a wide spectrum of signaling responses that mediate its physiological control of renal and cardiovascular function, including blood pressure. Upon activation by angiotensin II (Ang II), AT1R is internalized into early endosomes via regulation of Rab5, trafficked to late endosomes via regulation of Rab7 and to lysosomes. The occurrence of fluorescence resonance energy transfer (FRET) between AT1R and LAMP1 (a lysosome marker) confirms the trafficking of AT1R into lysosomes for eventual degradation. Latrunculin A but not nocodazole blocks the Ang II-induced FRET between AT1R and Rab5 or Rab7, indicating the requirement of intact actin but not microtubule cytoskeleton in the regulation of AT1R endocytic trafficking. However, upon activation of dopamine D5 receptor (D5R), the lifetime of AT1R is significantly shortened in the presence of ubiquitin as the acceptor fluorophore, suggesting that a fraction of AT1R is ubiquitinated and processed for proteasomal degradation. Some of the internalized AT1Rs escape degradation and coordinately via Rab4 and Rab11, recycle back to the plasma membrane. Both AT1R and D5R are expressed in the cholesterol-rich membrane lipid rafts, and portions of Rab4 (12.1±3.5%) and Rab11 (16.7±6.3%) in the same lipid rafts of sucrose gradient fractions in the AT1R/D5R HEK 293 cells. Therefore, the degradation of AT1R involves both lysosomes and proteasomes. The recognition of the diversity of AT1R intracellular trafficking and degradation may lead to a better understanding of AT1R-mediated regulation of blood pressure.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Hewang Lee”
- BylineArticles whose byline prints “Robin A. Felder”
- BylineArticles whose byline prints “Pedro A. Jose”
